
- /
- Supported exchanges
- / US
- / PDSB.NASDAQ
PDS Biotechnology Corp (PDSB NASDAQ) stock market data APIs
PDS Biotechnology Corp Financial Data Overview
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies. The company's lead product candidate is Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein for treating acute myeloid leukemia, prostate, and breast cancer; and PDS0103 for ovarian, breast, colorectal, and lung cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate, tumor-targeting interleukin 12 immune-cytokine that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment. Further, the company provides PDS0202, a novel investigational influenza vaccine that protects against the strains predicted to be prevalent in an upcoming flu season. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Princeton, New Jersey.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get PDS Biotechnology Corp data using free add-ons & libraries
Get PDS Biotechnology Corp Fundamental Data
PDS Biotechnology Corp Fundamental data includes:
- Net Revenue:
- EBITDA: -35 268 812
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-13
- EPS/Forecast: -0.2467
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
PDS Biotechnology Corp News

PDS Biotech to Host Key Opinion Leader Event to Discuss Versamune® HPV for the Treatment of HPV16+ HNSCC
Event to Discuss the Changing Landscape of HNSCC in context with the Merck KN-689 study and the Rapidly Increasing Incidences of HPV16-positive HNSCC in the United States and Europe Webinar to be hel...


PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
Phase 2: Versamune® HPV with pembrolizumab as 1L treatment of r/m HPV16-positive HNSCC - Median overall survival for CPS ≥20 is 39.3 months - Median overall survival for CPS ≥1 is 30.0 months ...

PDS Biotech to Participate at the A.G.P. Virtual Annual Healthcare Company Showcase
PRINCETON, N.J., May 20, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming ho...

PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
PRINCETON, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming ho...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.